Januvia is a prescription medication marketed by Merck Sharp & Dohme (MSD) that contains the active ingredient sitagliptin phosphate. It belongs to the therapeutic class of diabetes management and is available in pill form at strengths of 50 mg and 100 mg. In Hong Kong, Januvia is regulated by the Hong Kong Department of Health and can be obtained only with a physician’s prescription.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. By blocking the DPP-4 enzyme, it prevents the rapid breakdown of incretin hormones (GLP-1 and GIP). These hormones:
Because the effect is glucose-dependent, the risk of low blood sugar (hypoglycemia) is low when sitagliptin is used alone. The medication reaches peak plasma concentrations about 2-4 hours after ingestion, with a half-life of roughly 12 hours, supporting once-daily dosing.
Januvia is approved in Hong Kong for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise. It may be used:
Januvia is not approved for type 1 diabetes, gestational diabetes, or diabetic ketoacidosis.
These effects are usually mild and transient.
This article provides educational information about Januvia and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Januvia is frequently combined with metformin, sulfonylureas, or pioglitazone to improve glycemic control. However, the combination may increase the risk of hypoglycemia, especially with sulfonylureas, so blood glucose should be monitored closely.
Persistent, severe abdominal pain could be a sign of pancreatitis. Seek immediate medical attention, and your provider will likely discontinue the medication pending evaluation.
Clinical trials have not shown an increased risk of cardiovascular events with sitagliptin. Nevertheless, patients with established heart disease should discuss any new medication with their cardiologist or primary care physician.
All DPP-4 inhibitors share the same mechanism of prolonging incretin activity. Differences lie in dosing convenience, renal adjustment guidelines, and specific side-effect profiles. Januvia offers once-daily dosing with 50 mg and 100 mg tablet strengths.
Januvia tablets are permitted in carry-on luggage. Keep them in the original prescription label or a pharmacist-verified medication bag to avoid delays at security checkpoints.
The standard Januvia tablet formulation does not contain lactose, gluten, or other common food allergens. For patients with specific excipient sensitivities, consult the product’s full ingredient list or a pharmacist.
Yes, generic sitagliptin tablets are available and are therapeutically equivalent to Januvia. They are typically marketed under the name “Sitagliptin Phosphate” and come in the same 50 mg and 100 mg strengths.
Most patients experience a measurable decrease in fasting glucose within 1-2 weeks, with maximal HbA1c improvement observed after 12-24 weeks of consistent therapy.
Maintain the tablets at room temperature, avoiding exposure to temperatures above 30 °C for prolonged periods. If you live in a humid environment, keep the bottle tightly closed and store it in a cool, dry place.
Sitagliptin is classified as Category B (no proven risk in animal studies, but insufficient human data). It should only be used during pregnancy if the potential benefit justifies the potential risk and after thorough discussion with a healthcare professional.
